wellrank.ai

My insurance denied Wegovy. Are compounded GLP-1s my best option?

ClaudediscoveryCollected Jun 17, 2026, 13:17 UTC

Verbatim response from Claude

This is a common situation, and compounded GLP-1s are worth considering, but here's a clear picture of your options:

Compounded Semaglutide Options

Hims/Hers, Ro (Body Program), and Henry Meds are reputable telehealth platforms offering compounded semaglutide. They typically run $200-$400/month, which is significantly less than Wegovy's list price.

Important caveats:

  • Quality varies by compounding pharmacy
  • FDA has raised some safety concerns about compounded versions
  • These are not FDA-approved products

Other Options to Consider First

Appeal your denial - Many denials get overturned. Your doctor can submit a prior authorization appeal with documentation of medical necessity.

Manufacturer savings programs - Novo Nordisk's savings card can reduce Wegovy to around $650/month or sometimes less if you qualify.

Try Zepbound (tirzepatide) - Sometimes insurers cover one GLP-1 but not another. It's worth asking your doctor about this.

Lilly's savings program - Zepbound has a vial program through Lilly for roughly $399/month for self-pay patients.

My Honest Recommendation

Start with an appeal AND check Zepbound coverage simultaneously before going compounded. Compounded is a reasonable backup, but name-brand programs may be more affordable than you think.

Would you like more detail on any of these?

Brands mentioned in this answer

Is this answer wrong about your brand?

AI engines repeat outdated pricing, wrong ingredients, and misread positioning every day. Tell us what this answer gets wrong and we will include a correction review in your free AI Visibility Audit.

This answer is reproduced verbatim from the engine's API at collection time and may contain errors or outdated claims. It is presented as evidence of what AI engines tell buyers, not as medical or purchasing advice.

Is your brand missing from this answer?

Get your AI Visibility Audit: every buyer intent question you are losing, who wins them, and the sources that decide the answer.